Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;2(3):301-13.

Optimizing efficacy of Amphotericin B through nanomodification

Gillian Barratt  1 , Stéphane Bretagne
Affiliations
Review

Optimizing efficacy of Amphotericin B through nanomodification

Gillian Barratt et al. Int J Nanomedicine. 2007.

Abstract

The polyene antibiotic Amphotericin B (AMB) is one of the first therapeutic agents to be marketed commercially as nanosized formulations in which the drug is associated with lipids as liposomes or complexes. In this way, its renal toxicity is reduced and its therapeutic index improved. This review summarizes the particular properties of AMB which justify this type of formulation and the early work leading up to their development. The clinical results obtained in the treatment of fungal infections are reviewed and their activity against leishmaniasis is also evoked. Some newer formulations of AMB, based on both lipids and polymers are described. In particular, their potential by the oral and pulmonary routes are discussed. Finally, the development of targeted systems to deliver the drug to specific cells and tissues is considered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of Amphotericin B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams M, Kwon GS. Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying and reconstitution of polymeric micelles. J Pharm Pharmaceut Sci. 2004;7(S1):1–6. - PubMed
    1. Adler-Moore JP, Proffitt R. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Ther. 2002;49(Suppl1):21–30. - PubMed
    1. Agrawal AJ, Agrawal A, Pal A, et al. Superior chemotherapeutic efficacy of Amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target. 2002;10:41–5. - PubMed
    1. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025–32. - PubMed
    1. Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 2004;92:127–32. - PubMed

MeSH terms

LinkOut - more resources